[Pre-print, not peer-reviewed]<\/i> A study assessing whether CD8+ T-cells from COVID-19 convalescent individuals (n=30) can recognize SARS-CoV-2 variant epitopes showed that only one of the three most prominent variants (the B.1.351 variant, first described in South Africa) had a mutation that overlapped with a low-prevalence CD8+ epitope. Out of 45 mutations assessed, this mutation was found on the third residue of the epitope. The authors argue that these findings suggest that virtually all anti-SARS-CoV-2 CD8+ T-cell responses should recognize these newly described variants.<\/p>\n
Redd et al. (Feb 2021). CD8+ T Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes from Multiple Prominent SARS-CoV-2 Circulating Variants. Pre-print downloaded Feb 17 from <\/i>https:\/\/doi.org\/10.1101\/2021.02.11.21251585<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" [Pre-print, not peer-reviewed] A study assessing whether CD8+ T-cells from COVID-19 convalescent individuals (n=30) can recognize SARS-CoV-2 variant epitopes showed that only one of the three most prominent variants (the B.1.351 variant, first described in South Africa) had a mutation that overlapped with a low-prevalence CD8+ epitope. Out of 45 mutations assessed, this mutation was…<\/p>\n